Janssen Announces Data from Simeprevir in Hepatitis C Patients Will be Presented at the International Liver Congress of the European Association for the Study of the Liver (EASL)
4/8/2013 6:16:23 AM
CORK, Ireland, April 8, 2013 /PRNewswire/ --Janssen R&D Ireland (Janssen) announces that data will be presented on the investigational protease inhibitor simeprevir (TMC435) for the treatment of hepatitis C at The International Liver Congress 2013 of the European Association for the Study of the Liver (EASL), which will take place April 24 to 28 in Amsterdam, The Netherlands. These data presentations will include primary efficacy and safety results from the Phase 3 QUEST-1 study of simeprevir administered once daily in combination with pegylated interferon and ribavirin in treatment-naive genotype 1 chronic hepatitis C patients.
comments powered by